je.st
news
Oncolytics Biotech Receives Buy Rating from Paradigm Capital
2014-09-17 19:36:48| Biotech - Topix.net
's stock had its "buy" rating reissued by investment analysts at Paradigm Capital in a note issued to investors on Wednesday. They currently have a C$8.00 price objective on the stock, down from their previous price objective of C$10.00.
Tags: buy
rating
capital
receives
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||